Cullinan Therapeutics (CGEM) vs 4D Molecular Therapeutics (FDMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
4D Molecular Therapeutics (FDMT) has outperformed Cullinan Therapeutics (CGEM) over the past year, losing 5.6% versus a loss of 6.1%. Over five years, CGEM leads with a -51.2% price change compared with -53.6% for FDMT. Cullinan Therapeutics is the larger company by market cap ($577.1 million vs $576.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGEM | FDMT |
|---|---|---|
| Share price | $8.89 | $10.23 |
| Market cap | $577.15M | $576.76M |
| 1-day change | -1.98% | -4.57% |
| YTD return | -14.11% | +36.40% |
| 1-year return | -6.12% | -5.63% |
| 5-year return | -51.21% | -53.61% |
| EPS (TTM) | $-3.09 | $-2.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $85.21M |
| Revenue growth (YoY) | — | +230194.59% |
| Net income (latest FY) | $-219.88M | $-140.11M |
| Operating margin | — | -187.24% |
| Net margin | — | -164.43% |
| 52-week high | $23.19 | $16.93 |
| 52-week low | $8.47 | $6.96 |
| Distance from 52-week high | -61.66% | -39.57% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +285.49% | +174.58% |
| Average volume | 997.14K | 967.00K |
| Shares outstanding | 64.92M | 56.38M |
| Employees | 109 | 196 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cullinan Therapeutics
CGEM stock →Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees
About 4D Molecular Therapeutics
FDMT stock →4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 196 employees
CGEM vs FDMT FAQ
Which is bigger, Cullinan Therapeutics or 4D Molecular Therapeutics?
Cullinan Therapeutics (CGEM) is larger, with a market capitalization of $577.15M compared with $576.76M for 4D Molecular Therapeutics (FDMT).
Which stock has performed better over the past year, CGEM or FDMT?
FDMT returned -5.63% over the past 12 months, compared with -6.12% for CGEM (price return, excluding dividends). Past performance does not predict future results.
Are Cullinan Therapeutics and 4D Molecular Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.